FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Proliferation topics
Proliferation
Cell Proliferation
Differentiation
Cancer Cell
Antibodies
Progesterone
Specificity
Cancer Cells
Antimicrobial
Lymphocyte
Cell Differentiation
Homogeneous
Amino Acids
Wound Healing
Epithelial

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Proliferation patents



      
           
This page is updated frequently with new Proliferation-related patent applications. Subscribe to the Proliferation RSS feed to automatically get the update: related Proliferation RSS feeds. RSS updates for this page: Proliferation RSS RSS


Date/App# patent app List of recent Proliferation-related patents
01/29/15
20150031682
 Anti-malarial agents patent thumbnailnew patent Anti-malarial agents
The present invention is related to a use of aminopyrazine derivatives in the manufacture of a medicament for preventing or treating malaria. Specifically, the present invention is related to aminopyrazine derivatives useful for the preparation of a pharmaceutical formulation for the inhibition of malaria parasite proliferation..
Mmv Medicines For Malaria Venture
01/29/15
20150030854
 Vitamin b6-coupled poly(ester amine) as gene carrier and application in cancer gene therapy patent thumbnailnew patent Vitamin b6-coupled poly(ester amine) as gene carrier and application in cancer gene therapy
The present invention relates to a vitamin b6-coupled poly(ester amine) (vbpea) as a gene carrier and a method for preparing the gene carrier. Moreover, the present invention relates to a gene delivery complex comprising a therapeutic gene coupled to the gene carrier and a pharmaceutical formulation for gene therapy, which comprises the gene delivery complex as an active ingredient.
Snu R&db Foundation
01/29/15
20150030688
 Honey and growth factor eluting scaffold for wound healing and tissue engineering patent thumbnailnew patent Honey and growth factor eluting scaffold for wound healing and tissue engineering
Tissue engineering structures with biologically favorable structural and chemical properties are disclosed. More particularly, the present disclosure is directed to tissue engineered scaffolds having a fiber support and honey.
Saint Louis University
01/29/15
20150030634
 Proliferating agent for monocyte, culture medium for proliferating monocyte,  producing monocyte,  producing dendritic cell, and  producing dendritic cell vaccine patent thumbnailnew patent Proliferating agent for monocyte, culture medium for proliferating monocyte, producing monocyte, producing dendritic cell, and producing dendritic cell vaccine
The purpose of the present invention is to provide a means for proliferating a monocyte with high efficiency and in a simple manner. The present invention provides a proliferating agent for a monocyte, which consists of at least one component selected from flt-3l, il-3 and ifn-γ and can be used before a treatment for differentiation of a monocyte into a dendritic cell.
Hakushikouseikai Foundation
01/29/15
20150030585
 Compositions including triciribine and one or more platinum compounds and methods of use thereof patent thumbnailnew patent Compositions including triciribine and one or more platinum compounds and methods of use thereof
This application encompasses combination therapies including triciribine and related compounds and one or more platinum compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.. .
University Of South Florida
01/22/15
20150025230
 Single nucleotide polymorphisms in brca1 and cancer risk patent thumbnailSingle nucleotide polymorphisms in brca1 and cancer risk
The invention provides methods for identifying mutations, such as single nucleotide polymorphisms (snps), within breast and ovarian cancer associated genes that modify the binding efficacy of micrornas (mirnas). In a preferred embodiment, methods of the invention identify a snp that decreases expression of the brca1 gene by increasing or decreasing the binding efficacy of at least one mirna.
Yale University
01/22/15
20150023951
 Anti-vegf antibodies patent thumbnailAnti-vegf antibodies
Humanized and variant anti-vegf antibodies and various uses therefor are disclosed. The anti-vegf antibodies have strong binding affinities for vegf; inhibit vegf-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo..
Genentech, Inc.
01/22/15
20150023868
 Hif inhibitors and use thereof patent thumbnailHif inhibitors and use thereof
The present invention is directed to hif inhibitors and methods of preventing cell proliferation, reducing inflammation, and treating an angiogenic disease or disorders.. .
The General Hospital Corporation
01/15/15
20150018364
 Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics patent thumbnailControl of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics
The present invention relates to oligooxopiperazines that mimic helix αb of the c-terminal transactivation domain of hif-1α. Also disclosed are pharmaceutical compositions containing these oligooxopiperazines and methods of using these oligooxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of hif-1α with creb-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation)..
University Of Southern California
01/15/15
20150018310
 Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors patent thumbnailSubstituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.. .
Allergan, Inc.
01/15/15
20150018290

Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders


The present invention generally relates to compositions containing chemical compounds and compositions and pharmaceutical formulations of the compounds which increase the expression of total hemoglobin or globin protein such as embryonic or fetal globin, or the proliferation of hemoglobin expressing and other blood cells. These compositions can be used to treat or prevent the symptoms associated with anemia, sickle cell diseases, thalassemia, and other blood cell deficiencies and blood disorders.
Trustees Of Boston University
01/15/15
20150018286

Antitumor peptide and use thereof


This invention provides an antitumor peptide and an antitumor composition that includes the peptide for suppressing proliferation of at least one species of tumor cells. The antitumor composition provided by this invention includes an antitumor peptide capable of inducing formation of multipolar spindles in at least one species of tumor cells, and at least one species of pharmaceutically acceptable carrier, wherein the antitumor peptide is a synthetic peptide having an amino acid sequence selected from seq id nos: 1 to 22 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the selected amino acid sequence..
Toagosei Co., Ltd.
01/15/15
20150018225

Cell adhesion inhibitor, cell proliferation inhibitor, and method and kit for examining cancer


According to one aspect of the present invention, there is provided a cell proliferation inhibitor or a cell adhesion inhibitor for a cancer cell, containing an antibody to a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by seq id no: 2 or a partial peptide thereof. According to another aspect of the present invention, there is provided a cell adhesion inhibitor for a cancer cell, containing an antisense polynucleotide containing a complementary or substantially complementary base sequence to a base sequence of a polynucleotide encoding a protein containing the same or substantially the same amino acid sequence as the amino acid sequence represented by seq id no: 2 or a part thereof.
01/15/15
20150017726

Media for stem cell proliferation and induction


The present application discloses a cell culture media for growth, maintenance and induction of reversion to a less mature state of a cell comprising a muc1* activating ligand.. .
Minerva Biotechnologies Corporation
01/15/15
20150017721

Method for inducing proliferation of natural killer cells by mobile nanomatrices


The present invention provides an in-vitro method for inducing proliferation of nk cells, the method comprising contacting a population of nk cells with a nanomatrix, the nanomatrix comprising a) a matrix of mobile polymer chains; and b) attached to said matrix of mobile polymer chains one or more stimulatory agents which provide activation signals to the nk cells; thereby activating and inducing the nk cells to proliferate; wherein the nanomatrix is 1 to 500 nm in size. At least one first and one second stimulatory agents are attached to the same or to separate flexible matrices.
Miltenyi Biotec Gmbh
01/15/15
20150017262

Inhibition of dynamin related protein 1 to promote cell death


The present invention relates to compositions and methods for reducing cell proliferation and/or promoting cell death by inhibiting drp1. It is based, at least in part, on the discoveries that (i) drp1 disruption-induced mitochondrial hyperfusion is functionally linked to the cell cycle regulation apparatus, so that drp1 inhibition results in a disruption of the cell cycle and dna aberrancies; (ii) inhibition of both drp1 and atr are synthetic lethal causing increased dna damage and apoptotic cell death; and (iii) even in resistant cell lines, drp1 inhibitor (e.g., mdivi-1) together with a second antiproliferative agent (e.g., cisplatin or carboplatin) act synergistically to promote apoptosis.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education
01/08/15
20150013024

Near-infrared light-activated proteins


Methods and constructs are provided for controlling processes in live animals, plants or microbes via genetically engineered near-infrared light-activated or light-inactivated proteins including chimeras including the photosensory modules of bacteriohytochromes and output modules that possess enzymatic activity and/or ability to bind to dna, rna, protein, or small molecules. Dna encoding these proteins are introduced as genes into live animals, plants or microbes, where their activities can be turned on by near-infrared light, controlled by the intensity of light, and turned off by near-infrared light of a different wavelength than the activating light.
University Of Wyoming
01/08/15
20150011611

Inhibition of the glycine cleavage system for treatment of cancer


In some aspects, methods of inhibiting survival or proliferation of a tumor cell are provided, the methods comprising inhibiting the glycine cleavage system (gcs) of the tumor cell. In some aspects, methods of treating a subject in need of treatment for a tumor, the method comprising inhibiting the gcs in the tumor.
Whitehead Institute For Biomedical Research
01/08/15
20150011609

Micrornas for cardiac regeneration through induction of cardiac myocyte proliferation


The present invention discloses a set of human micrornas, or a primary transcript for such micrornas, or a precursor of such micrornas, or a mimic of such micrornas or a combination thereof, and their use as medicaments for inducing proliferation of cardiomyocytes for the prevention and treatment of heart diseases associated with a loss of cardiomyocytes. The invention also relates to a method for screening micrornas and biological and therapeutically active compounds for their ability to increase proliferation of cardiomyocytes..
International Centre For Genetic Engineering And Biotechnology - Icgeb
01/08/15
20150011565

Heterocyclic compounds and methods for their use


The present invention relates to heterocyclic compounds useful for antagonizing angiotensin ii type 2 (at2) receptor. More particularly the invention relates to piperazine and diazepine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration..
Spinifex Pharmaceuticals Pty Ltd
01/08/15
20150011547

Substituted quinazoline and pyrido-pyrimidine derivatives


The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds.
Asana Biosciences, Llc
01/08/15
20150011492

Anti-restenosis compositions and methods


The present invention relates generally to the pathology of restenosis. In particular, provided herein are devices comprising a compound that selectively decreasing smooth muscle cell proliferation without a substantial decrease in endothelial cell proliferation.
Wisconsin Alumni Research Foundation
01/08/15
20150011466

Apj receptor compounds


The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the g protein coupled receptor apelin, also known as the apj receptor. The apj receptor compounds are derived from the it intracellular loop and domain of the apj receptor.
Anchor Therapeutics, Inc.
01/08/15
20150011002

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents


The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.. .
Rigel Pharmaceuticals, Inc.
01/08/15
20150010946

Polynucleotides encoding zcytor17 ligand antibodies


The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine.
Zymogenetics, Inc.
01/08/15
20150010715

Antimicrobial coating for inhibition of bacterial adhesion and biofilm formation


The present invention provides antimicrobial coatings for coating substrate surfaces, particularly medical devices, for preventing bacterial adhesion and biofilm formation by inhibiting microbial growth and proliferation on the coating surface. The antimicrobial coatings are composed of a hydrogel and a bioactive agent including a substantially water-insoluble antimicrobial metallic material that is solubilized within the coating.
Bacterin
01/08/15
20150010615

Supercritical guggul extracts and uses thereof


The subject invention pertains to supercritical carbon dioxide extracts of commiphora mukul resin (guggul), which can be modified or not modified by some ethanol addition; methods for their production; and methods of use, such as inhibiting hmg-coa reductase, inhibiting transformation of pre-adipocytes to adipocytes, inhibiting triglyceride storage, promoting insulin sensitivity in adipocytes, treatment of disorders (for example, hypercholesterolemia, hyperlipidemia, hyperglycemia, obesity, metabolic syndrome, cardiovascular disease, atherosclerotic heart disease, autoimmune disorder, insulin resistance, leptin resistance, arthritis, cell proliferation disorder, such as cancer and atherosclerosis; damaged skin, sores, cuts, rashes, bruises, dryness, burns, sunburn, radiation burn, and infection), and regulating or suppressing appetite.. .
Flavex Naturextrakte Gmbh
01/08/15
20150010613

Compositions and methods for cancer immunotherapy


The present invention provides a combination therapy which relies on a small molecule immune stimulator—cyclic-di-nucleotide (cdn)—that activates dcs via a recently discovered cytoplasmic receptor known as sting (stimulator of interferon genes) formulated with allogeneic human tumor cell lines engineered to secrete high amounts of gm-csf. This combination therapy can provide an ideal synergy of multiple tumor associated antigens, dc recruitment and proliferation, coupled with a potent dc activation stimulus..
Aduro Biotech
01/08/15
20150010577

Translocation and mutant ros kinase in human non-small cell lung carcinoma


In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (nsclc) that results in a fusion proteins combining part of cd74 with proto-oncogene tyrosine protein kinase ros precursor (ros) kinase has now been identified. The cd74-ros fusion protein is anticipated to drive the proliferation and survival of a subgroup of nsclc tumors.
Cell Signaling Technology, Inc.
01/08/15
20150010561

Semaphorin 3c (sema3c) inhibitor therapeutics, methods, and uses


Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a sema3c inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (ar) positive prostate cancer and the sema3c inhibitor may be selected from one or more of the following: an antibody, a sema3c peptide, an antisense rna, a sirna, a shrna or a small molecule..
The University Of British Columbia
01/01/15
20150005387

Composition containing agmatine, and uses thereof in preparing drugs or neutraceutical substances


The present invention relates to novel compositions including a mixture of cadaverine, putrescine, spermine and spermidine at a concentration ranging from 0.31 to 0.63 nmol per gram of composition, the composition also including agmatine at a concentration ranging from 120 to 17100 nmol per gram of composition, and uses thereof in the treatment, in a patient, of pathologies associated with cellular hyperproliferation.. .
Nutrialys Medical Nutrition Sa
01/01/15
20150005381

Method for modulating stem cell growth


In one embodiment, provided is a composition including a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is directed to a composition which includes a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of a mammalian subject, in which the stem cells are contacted directly or indirectly with the composition of the invention..
Sucampo Ag
01/01/15
20150005374

Compounds and methods for delivery of prostacyclin analogs


This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.. .
United Therapeutics Corporation
01/01/15
20150005343

Use of eribulin and lenvatinib as combination therapy for treatment of cancer


The invention provides methods and compositions for use in treating diseases associated with excessive cellular proliferation, such as cancer.. .
Eisai R&d Management Co., Ltd.
01/01/15
20150004693

Mesenchymal stem cells expressing tnf-alpha receptors


Mesenchymal stem cells which express tnf-α receptor type i in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease..
Mesoblast International Sarl
01/01/15
20150004207

Interventional medical device and manufacturing method thereof


An interventional medical device and manufacturing method thereof, the interventional medical device comprising a stent body (1); the stent body (1) is provided with a drug releasing structure on the surface, the drug in the drug releasing structure being a drug for inhibiting adventitial fibroblast proliferation. When the interventional medical device is implanted into a human body, the drug for inhibiting the adventitial fibroblast proliferation can be slowly released into vessel wall cells in contact with the stent body (1), thus inhibiting the proliferation of the adventitial fibroblasts, promoting vascular compensatory expansion, and reducing the incidence rate of instent restenosis..
Shanghai Microport Medical (group) Co., Ltd.
01/01/15
20150004178

Anti-human sema4a antibodies useful to treat disease


Anti-human sema4a antibodies useful in treating autoimmune diseases, cancers and other disease are provided herein. Anti-human sema4a antibodies can inhibit t cell proliferation and th2 differentiation induced by il-4, anti-cd3, anti-cd28 and recombinant sema4a..
Board Of Regents, The University Of Texas System
01/01/15
20150004172

Hypoxia-induced mitogenic factor


We found that fizz1/relmα is inducible by hypoxia in lung. The hypoxia-upregulated expression of fizz1/relmα was located in the pulmonary vasculature, bronchial epithelial cells, and type ii pneumocytes.
The Johns Hopkins University
12/25/14
20140378524

Methods and compositions comprising akt inhibitors and/or phospholipase d inhibitors


Disclosed are methods of treating viral infections or disorders of uncontrolled proliferation comprising, in one aspect, administering compounds that are phospholipase d inhibitors and/or akt therapeutic agents. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
Vanderbilt University
12/25/14
20140378515

Immunosuppressive compounds


The invention feature series of benzothiazole derivatives as potent immunosuppressive and antiinflammatory agents. Eight compounds 2, 4, 5, 8, 9, 10, 12, and 18 showed potent inhibitory activity on pha-activated t-cell proliferation.
12/25/14
20140378511

Pyridine derivatives


The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
Asana Biosciences, Llc
12/25/14
20140378503

Anti-cancer compounds


The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation..
Northwestern University
12/25/14
20140378430

Heterocyclic compounds and methods of their use


The present invention relates to heterocyclic compounds useful for antagonising angiotensin ii type 2 (at2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with at2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration..
Spinifex Pharmaceuticals Pty Ltd
12/25/14
20140377781

Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same


Monoclonal antibodies that bind specifically to claudin 3 expressed on cell surface are provided. The antibodies of the present invention are useful for diagnosis of cancers that have enhanced expression of claudin 3, such as ovarian cancer, prostate cancer, breast cancer, uterine cancer, liver cancer, lung cancer, pancreatic cancer, stomach cancer, bladder cancer, and colon cancer.
Chugai Seiyaku Kabushiki Kaisha
12/25/14
20140377277

Treatment of vasculoproliferative conditions with lrg1 anatgonists


This invention relates to the field of molecular physiology. Specifically, this invention relates to the treatment of vasculoproliferative conditions, especially those of the eye and in the treatment of tumours that exhibit vascular proliferation.
Ucl Business Plc
12/18/14
20140371215

1-h-pyrrolo[2,3-b]pyridine derivatives


1h-pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.. .
Merck Patent Gmbh
12/18/14
20140371205

Substituted pyrimidines for the treatment of diseases such as cancer


A, b, x, r1 to r3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.. .
12/18/14
20140371155

Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof


The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis.
Trustees Of Tufts College
12/18/14
20140371154

Nucleic acids encoding peptides for treating wounds, anti-angiogenic compounds and uses thereof


The present disclosure relates to protein and peptide chemistry. More particularly, it relates to compounds, compositions and uses thereof for promoting and inhibiting angiogenesis.
Trustees Of Tufts College


Popular terms: [SEARCH]

Proliferation topics: Proliferation, Cell Proliferation, Differentiation, Cancer Cell, Antibodies, Progesterone, Specificity, Cancer Cells, Antimicrobial, Lymphocyte, Cell Differentiation, Homogeneous, Amino Acids, Wound Healing, Epithelial

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Proliferation for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Proliferation with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.2961

3586

0 - 1 - 71